Summary A 54-year-old man had gastrinoma, parathyroid hyperplasia and pituitary tumor. His family history indicated that he might have multiple endocrine neoplasia type 1 (MEN1). MEN1 gene analysis revealed a heterozygous germline mutation (Gly156Arg). Therefore, we diagnosed him with MEN1. Endocrinological tests revealed that his serum prolactin (PRL) and plasma adrenocorticotropic hormone (ACTH) levels were elevated to 1699 ng/mL and 125 pg/mL respectively. Immunohistochemical analysis of the resected pancreatic tumors revealed that the tumors did not express ACTH. Overnight 0.5 and 8 mg dexamethasone suppression tests indicated that his pituitary tumor was a PRL-ACTH-producing plurihormonal tumor. Before transsphenoidal surgery, cabergoline was initiated. Despite no decrease in the volume of the pituitary tumor, PRL and ACTH levels decreased to 37.8 ng/mL and 57.6 pg/mL respectively. Owing to the emergence of metastatic gastrinoma in the liver, octreotide was initiated. After that, PRL and ACTH levels further decreased to 5.1 ng/mL and 19.7 pg/mL respectively. He died from liver dysfunction, and an autopsy of the pituitary tumor was performed. In the autopsy study, histopathological and immunohistochemical (IHC) analysis showed that the tumor was single adenoma and the cells were positive for ACTH, growth hormone (GH), luteinizing hormone (LH) and PRL. RT-PCR analysis showed that the tumor expressed mRNA encoding all anterior pituitary hormones, pituitary transcription factor excluding estrogen receptor (ER) β, somatostatin receptor (SSTR) 2, SSTR5 and dopamine receptor D (D2R). PRL-ACTH-producing tumor is a very rare type of pituitary tumor, and treatment with cabergoline and octreotide may be useful for controlling hormone levels secreted from a plurihormonal pituitary adenoma, as seen in this case of MEN1. Learning points: Although plurihormonal pituitary adenomas were reported to be more frequent in patients with MEN1 than in those without, the combination of PRL and ACTH is rare. RT-PCR analysis showed that the pituitary tumor expressed various pituitary transcription factors and IHC analysis revealed that the tumor was positive for PRL, ACTH, GH and LH. Generally, the effectiveness of dopamine agonist and somatostatin analog in corticotroph adenomas is low; however, if the plurihormonal pituitary adenoma producing ACTH expresses SSTR2, SSTR5 and D2R, medical therapy for the pituitary adenoma may be effective.
[1]
M. Fleseriu,et al.
Medical treatment of Cushing's Disease.
,
2016,
Minerva endocrinologica.
[2]
E. Capoluongo,et al.
Multiple endocrine neoplasia type 1 (MEN1): An update of 208 new germline variants reported in the last nine years.
,
2016,
Cancer genetics.
[3]
J. Romijn,et al.
Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
,
2009,
The Journal of clinical endocrinology and metabolism.
[4]
D. Figarella-Branger,et al.
Pituitary Tumors and Hyperplasia in Multiple Endocrine Neoplasia Type 1 Syndrome (MEN1): A Case-Control Study in a Series of 77 Patients Versus 2509 Non-MEN1 Patients
,
2008,
The American journal of surgical pathology.
[5]
M. Rosenfeld,et al.
Molecular physiology of pituitary development: signaling and transcriptional networks.
,
2007,
Physiological reviews.
[6]
J. Kros,et al.
Dopamine receptor expression and function in corticotroph pituitary tumors.
,
2004,
The Journal of clinical endocrinology and metabolism.
[7]
Jeffrey E. Lee,et al.
Genotype-phenotype analysis in multiple endocrine neoplasia type 1.
,
2002,
Archives of surgery.
[8]
R. Rubens,et al.
Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline
,
2002,
Journal of endocrinological investigation.
[9]
G. Sassolas,et al.
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
,
2002,
The Journal of clinical endocrinology and metabolism.
[10]
S. Melmed,et al.
Pituitary tumor registry: a novel clinical resource.
,
2000,
The Journal of clinical endocrinology and metabolism.
[11]
N. Yamashita,et al.
A case of ectopic ACTH syndrome associated with Zollinger-Ellison syndrome: long-term survival with chemical adrenalectomy.
,
1994,
Endocrine journal.
[12]
B. Scheithauer,et al.
Plurihormonal pituitary adenomas.
,
1986,
Seminars in diagnostic pathology.